Effects of Allergen Inhalation on Adenosine Receptor Expression in Sputum and Peripheral Blood

This study is ongoing, but not recruiting participants.

First Received: June 28, 2005 Last Updated: March 20, 2007 History of Changes

Sponsored by:	Groningen Research Institute for Asthma and COPD
Information provided by:	Groningen Research Institute for Asthma and COPD
ClinicalTrials.gov Identifier:	NCT00116311

Purpose

The purpose of this study is to determine whether asthmatics have different adenosine receptor expression profiles than healthy controls. We hypothesize that asthmatics will have increased adenosine receptor expression versus control subjects.

We also want to study the effects of allergen inhalation on adenosine receptor expression in asthmatics. We believe that adenosine receptor expression will be upregulated after allergen inhalation.

Both hypotheses are being tested in sputum and peripheral blood.

Condition	Intervention
Asthma Healthy	Behavioral: allergen inhalation Behavioral: withdrawal of medication Procedure: sputum induction

MedlinePlus related topics: Asthma

Drug Information available for: Adenosine

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Cross-Sectional, Defined Population, Prospective Study
Official Title:	Effects of Allergen Inhalation on Adenosine Receptor Expression and Mast Cell Activation in Peripheral Blood and Sputum of Asthmatics and Healthy Subjects

Further study details as provided by Groningen Research Institute for Asthma and COPD:

Estimated Enrollment:	20
Study Start Date:	July 2005
Estimated Study Completion Date:	February 2007

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Asthmatic Subjects - Inclusion Criteria:

Clinical diagnosis of asthma
Steroid naive or subjects not using their inhaled steroids for the last 4 weeks, short-acting beta-agonist for rescue medication
FEV1 > 70% of predicted
Positive skin prick test for house dust mite, cat or grass pollen
PC20 methacholine or histamine < 8 mg/ml

Asthmatic Subjects - Exclusion Criteria:

Use of systemic steroids in the previous 6 weeks
Asthma exacerbations in the previous 6 weeks
Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Healthy Subjects - Inclusion Criteria:

No airway complaints
FEV1 > 90% of predicted
Negative skin prick test
PC20 methacholine or histamine > 8 mg/ml

Healthy Subjects - Exclusion Criteria:

Use of steroids in the previous 6 weeks
Current or ex-smokers with ≥ 10 pack-years (≥ 2 pipe pack-years), ex smokers who stopped less than 1 year ago

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00116311

Locations

Netherlands
University Medical Center Groningen, Department of Pulmonology
Groningen, Netherlands, 9713 GZ

Sponsors and Collaborators

Groningen Research Institute for Asthma and COPD

Investigators

Principal Investigator:

Dirkje S Postma, prof. MD PhD

University Medical Center Groningen, Department of Pulmonology, hanzeplein 1, 9713 GZ Groningen, The Netherlands

More Information

No publications provided

Study ID Numbers:	METc2004-253
Study First Received:	June 28, 2005
Last Updated:	March 20, 2007
ClinicalTrials.gov Identifier:	NCT00116311 History of Changes
Health Authority:	Netherlands: Dutch Health Care Inspectorate

Keywords provided by Groningen Research Institute for Asthma and COPD:

Adenosine receptors
asthma
sputum
peripheral blood
healthy

Study placed in the following topic categories:

Vasodilator Agents
Bronchial Diseases
Asthma
Cardiovascular Agents
Healthy
Lung Diseases, Obstructive
Hypersensitivity
Respiratory Tract Diseases

Lung Diseases
Hypersensitivity, Immediate
Analgesics
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Adenosine
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Vasodilator Agents
Bronchial Diseases
Immune System Diseases
Physiological Effects of Drugs
Asthma
Cardiovascular Agents
Pharmacologic Actions
Lung Diseases, Obstructive
Hypersensitivity
Respiratory Tract Diseases

Sensory System Agents
Therapeutic Uses
Lung Diseases
Hypersensitivity, Immediate
Anti-Arrhythmia Agents
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Adenosine
Respiratory Hypersensitivity

ClinicalTrials.gov processed this record on May 07, 2009